Biomerica (BMRA) Cash & Equivalents (2010 - 2026)

Biomerica has reported Cash & Equivalents for 17 years, with the latest figure at $1.3 million in Q1 2026.

• Quarterly Cash & Equivalents fell 56.31% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $1.3 million (down 56.31% YoY) and the FY2025 annual result came in at $3.1 million, down 26.67% from the prior year.
• Cash & Equivalents retreated to $1.3 million in Q1 2026 per BMRA's latest filing, from $2.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $10.2 million in Q1 2022 and troughed at $1.3 million in Q1 2026.
• A 5-year average of $4.9 million and a median of $4.2 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents jumped 92.96% in 2022, then slumped 67.12% in 2023.
• Over 5 years, Cash & Equivalents stood at $5.1 million in 2022, then soared by 40.81% to $7.1 million in 2023, then tumbled by 66.75% to $2.4 million in 2024, then rose by 7.21% to $2.5 million in 2025, then plunged by 47.46% to $1.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $1.3 million, $2.5 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.